Teacher Retirement System of Texas Grows Holdings in Bio-Rad Laboratories, Inc. $BIO

Teacher Retirement System of Texas raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 19.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,409 shares of the medical research company’s stock after buying an additional 562 shares during the period. Teacher Retirement System of Texas’ holdings in Bio-Rad Laboratories were worth $823,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd grew its position in Bio-Rad Laboratories by 3,633.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares in the last quarter. Quarry LP purchased a new position in shares of Bio-Rad Laboratories in the 1st quarter worth about $29,000. Allworth Financial LP boosted its holdings in shares of Bio-Rad Laboratories by 260.0% in the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock worth $36,000 after purchasing an additional 104 shares in the last quarter. UMB Bank n.a. increased its position in shares of Bio-Rad Laboratories by 89.8% during the 2nd quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 79 shares during the last quarter. Finally, Headlands Technologies LLC raised its holdings in shares of Bio-Rad Laboratories by 64.1% during the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after buying an additional 139 shares in the last quarter. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Trading Down 0.5%

Shares of BIO opened at $305.07 on Friday. The stock has a market capitalization of $8.26 billion, a P/E ratio of -12.55 and a beta of 1.04. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $373.69. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. The firm has a fifty day simple moving average of $300.02 and a two-hundred day simple moving average of $267.45.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing the consensus estimate of $2.30 by ($0.04). The firm had revenue of $653.00 million for the quarter, compared to the consensus estimate of $651.30 million. Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. The business’s revenue was up .5% on a year-over-year basis. During the same period last year, the company posted $2.01 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on BIO shares. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Royal Bank Of Canada upped their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Wells Fargo & Company increased their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Citigroup lifted their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.